Laura Botti

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 4

Top Topics

Early Breast Cancer

Inflammatory Response

Top Venues

Cancer immunology research

Molecular cancer research : MCR

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Roberta Sulsenti, Giuseppina Beatrice Scialpi, Barbara Frossi, Laura Botti, Renata Ferri, Irene Tripodi, Annamaria Piva, Sabina Sangaletti, Davide Pernici, Valeria Cancila, Francesco Romeo, Claudia Chiodoni, Daniele Lecis, Francesca Bianchi, Irene Fischetti, Claudia Enriquez, Filippo Crivelli, Marco Bregni, Giuseppe Renne, Salvatore Pece, Claudio Tripodo, Carlo E M Pucillo, Mario Paolo Colombo, Elena Jachetti
Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer. Cancer immunology research 12 (9) (2024)
Roberta Sulsenti, Giuseppina Beatrice Scialpi, Barbara Frossi, Laura Botti, Renata Ferri, Irene Tripodi, Annamaria Piva, Sabina Sangaletti, Davide Pernici, Valeria Cancila, Francesco Romeo, Claudia Chiodoni, Daniele Lecis, Francesca Bianchi, Irene Fischetti, Claudia Enriquez, Filippo Crivelli, Marco Bregni, Giuseppe Renne, Salvatore Pece, Claudio Tripodo, Carlo E M Pucillo, Mario Paolo Colombo, Elena Jachetti
Intracellular osteopontin promotes the release of TNF by mast cells to restrain neuroendocrine prostate cancer. Cancer immunology research (2024)
Bianca Cioni, Silvia Ratti, Annamaria Piva, Irene Tripodi, Matteo Milani, Francesca Menichetti, Tiziana Langella, Laura Botti, Loris De Cecco, Claudia Chiodoni, Daniele Lecis, Mario Paolo Colombo
JMJD6 shapes a pro-tumor microenvironment via ANXA1-dependent macrophage polarization in breast cancer. Molecular cancer research : MCR (2023)
Milena Perrone, Claudia Chiodoni, Mara Lecchi, Laura Botti, Barbara Bassani, Annamaria Piva, Elena Jachetti, Matteo Milani, Daniele Lecis, Elda Tagliabue, Paolo Verderio, Sabina Sangaletti, Mario Paolo Colombo
ATF3 reprograms the bone marrow niche in response to early breast cancer transformation. Cancer research (2022)